Drug Dev
OSE Immunotherapeutics seeks partner for lead drug
Scrip chats with Alexis Peyroles, chief operating officer of OSE Immunotherapeutics, on the sidelines of the recent BIO-Europe® partnering meeting about the company's plans for commercializing lead drug, Tedopi (OSE-2102). Based in France, OSE Immunotherapeutics is a biotechnology company developing innovative immunotherapies that act on effector and suppressor cells to stimulate or inhibit the body's immune response, and to restore immune disorders in the fields of immuno-oncology, autoimmune diseases and transplantation. Tedopi, the company’s most advanced pipeline product, is currently in Phase III for non-small cell lung cancer.